Progress in antibody technology development

The development of antibodies and associated technologies continues to drive high-value deals. We look at recent trends in the field with help from DealForma.

The Korea Drug Development Fund and its ADCaptain Project are helping to bring novel antibody therapeutics through the development pipeline to patients in need.

With three decades of experience, over 200 client partnerships and several cell-line development platforms, Aragen Bioscience supports its global biopharma clients with end-to-end biologics development solutions and services.

Xentria is taking an innovative approach leveraging in vitro and pharmacokinetic models and the power of partnerships to co-develop accessible treatment options for patients with unmet needs.

GV20 Therapeutics’ platform decodes patients’ B cell responses with artificial intelligence to discover novel targets and antibodies simultaneously. Targets and antibodies are validated and de-risked computationally and experimentally.

Bioengineered Probiotic Yeast Medicines are oral, live therapeutics that express and secrete disease-targeting therapeutic molecules in situ for the treatment of gastrointestinal-related diseases. This synthetic biology approach offers advantages over conventional protein biologics and fulfils the dream of oral administration.

Swiss preclinical stage biotech company Mabylon is developing novel human-derived antibody therapeutics to treat allergies and neurological disorders.

Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.